Is the FDA's drug review process breaking down?

Since 1997 the US FDA has banned use of 11 prescription drugs because of serious side effects. The FDA says it's not the drug approval process but inappropriate prescribing that is responsible.

Written byJohn Borchardt
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The US Food and Drug Administration (FDA) has withdrawn 11 prescription drugs from the market since 1997. Serious side effects and patient deaths have forced these withdrawals.

Is the FDA's drug review process breaking down? According to Sidney Wolfe, Director the Health Research Group (part of Ralph Nader's Public Citizen advocacy organisation), "Changes in FDA review and approval policies in the past several years appear to have led to a significant decline in the safety and efficacy standards for new drugs." Under congressional pressure the FDA has accelerated its review process. In 1997, the Congress passed the Food and Drug Administration Modernization Act expanding use of 'fast track' approval mechanisms for drugs to treat life-threatening conditions and allowing use of surrogate endpoints in clinical trials. It also included a number of mechanisms for accelerating FDA review and changed the legal standard for new drug approval to a single clinical trial ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026, Issue 1

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Skip the Wait for Protein Stability Data with Aunty

Skip the Wait for Protein Stability Data with Aunty

Unchained Labs
Graphic of three DNA helices in various colors

An Automated DNA-to-Data Framework for Production-Scale Sequencing

illumina

Products

nuclera logo

Nuclera eProtein Discovery System installed at leading Universities in Taiwan

Brandtech Logo

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control

Biotium Logo

Biotium Launches GlycoLiner™ Cell Surface Glycoprotein Labeling Kits for Rapid and Selective Cell Surface Imaging

Colorful abstract spiral dot pattern on a black background

Thermo Scientific X and S Series General Purpose Centrifuges

Thermo Fisher Logo